Table 1.

A review of reported cases of nonmediastinal BCLu DLBCL/CHL.

Study	Cases	Age/sex	Site	Initial diagnosis	Immunohistochemical staining	Rebiopsy diagnosis	Treatment	Outcome
Index case	1 case	56/M	Right neck mass	Follicular lymphoma	CD20+, CD15+, CD30+, CD79a+, PAX5+, bcl-2, and bcl-6+; Ki-67 80% Negative for CD3, CD5, CD10, ALK-1 protein, EMA, and EBV (EBER by ISH) Cyclin D1 equivocal, CD21+ Large cells binucleated and multinucleated were noted	B cell lymphoma, unclassifiable	ACVBP + radiation	Good response
Iwaki et al. [16]	1 case	78/F	Ileocecal tumor	Nodular sclerosis cHL	+ for CD30, CD20, CD79a, PAX5, BOB.1, and OCT-2, but negative for CD15 Increased level of soluble IL-2 receptor	BCLu-DLBCL/CHL	ABVD	Partial response
Wang et al. [17]	1 case	67/F	Left supraclavicular LN, right axillary LN, bilateral inguinal LAD	NA	CD30 and CD15+; CD20−, PAX5, and CD45 were down-regulated; EBV+	EBV + DLBCL and EBV + CHL	NA	NA
Eberle et al. [9]	1 case	55/M	Neck LN	NA	CD20+, CD30+, CD15, CD79a+, BOB.1+, Oct-2+, p63−, cyclin E−, and HLA-DR4	GZL	NA	NA
Eberle et al. [9]	1 case	67/F	Neck mass	NA	CD20+, CD30+, CD15−, CD79a+, BOB.1+, Oct-2+, p63+, cyclin E+, and HLA-DR4	GZL	NA	NA
Eberle et al. [9]	1 case	58/F	Inguinal LN	NA	CD20+, CD30−, CD15, CD79a+, BOB.1+, Oct-2+, p63−, cyclin E−, and HLA-DR4	GZL	NA	NA
Eberle et al. [9]	1 case	26/M	Neck mass	NA	CD20+, CD30+, CD15+, CD79a+, BOB.1+, Oct-2+, p63−, cyclin E+, and HLA-DR3	GZL	NA	NA
Eberle et al. [9]	1 case	91/F	Axillary LN	NA	CD20−, CD30+, CD15+, CD79a+ BOB.1+, Oct-2+, p63+, cyclin E+, and HLA-DR4	GZL	NA	NA
Eberle et al. [9]	1 case	24/F	Cervical LN	NA	CD20+, CD30+, CD15+, CD79a+, BOB.1+, Oct-2+, p63−, cyclin E+, and HLA-DR4	GZL	NA	NA
Eberle et al. [9]	1 case	48/F	Axillary LN	NA	CD20+, CD30+, CD15+, CD79a+, BOB.1+, Oct-2+, p63+, cyclin E+, and HLA-DR1	GZL	NA	NA
Eberle et al. [9]	1 case	85/M	Axillary mass	NA	CD20+, CD30+, CD15− CD79a+, BOB.1+, OCT2+, p63−, cyclin E+, and HLA-DR4	GZL	NA	NA
Eberle et al. [9]	1 case	25/F	Neck LN	NA	CD20− CD30+, CD15+, CD79a−, BOB.1−, Oct-2−, p63−, cyclin E−, and HLA-DR3	GZL	NA	NA
Quintanilla-Martinez et al. [12]	1 case (under subheading: “Classical Hodgkin's lymphoma with immunophenotypic deviations”)	38 yo	Axillary LN	NA	CD20+, PAX5−, OCT-2−, and CD79a−	CHL morphology but strong CD20 expression in the RS cells	NA	NA
Gualco et al. [14]	10 cases	37 y median age	8 mediastinal, 2 extramediastinal	NA	CD30+ (100%), CD20+ (100%), CD45+ (95%), CD15+ (40%), BOB1+ (40%), OCT2 (50%+, 30%), PAX5+ (90%), bcl-6 (40%), P63 (50%+), and CD79a (70%+)	B cell lymphoma, unclassifiable	combination chemotherapy for non-Hodgkin's lymphomas	Good response
García et al. [5]	9 cases	Young males	3 extramediastinal, 6 mediastinal	NA	CD30+, CD15+ (6/9)  CD45RB+, CD20+, CD79a+, OCT2+, and EBV (2/9)	Shared features of DLBCL and classical HL	NA	NA
Nadeem et al. [10]	49 cases; 11% extramediastinal	33.5 Y median age; M > F	11% extramediastinal, 89% mediastinal	NA	CD20+ (90%), CD30+ (95%), 63% CD15+, and EBV+ (9/22 patients)	GZL	Initial cHL regimens (BEACOPP, ABVD) or DLBCL regimens (CHOP, EPOCH, with or without rituximab)	7 pts received ABVD, 57% NR and 43% PR; no CRs 7 pts received CHOP; 5 had clinical outcome data available; 80% CR (received consolidation radiation therapy) and 20% PR 7 pts received autologous SCT and 2 of them had relapse in 6 months
Zarate-Osorno et al. [18]	9 cases: 7 follicular, 1 DLBCL, and 1 large cell immunoblastic	54-year median age	7 (primarily nodal)  Name of node not specified in the article	NHL	RS and Hodgkin's cells were LeuM1 or BerH2+ and LCA− in 8/9 biopsies	HD	4 chemotherapies  3 chemotherapies + radiation	NA